275 related articles for article (PubMed ID: 18711190)
1. Economic evaluation of sunitinib malate for the first-line treatment of metastatic renal cell carcinoma.
Remák E; Charbonneau C; Négrier S; Kim ST; Motzer RJ
J Clin Oncol; 2008 Aug; 26(24):3995-4000. PubMed ID: 18711190
[TBL] [Abstract][Full Text] [Related]
2. Economic evaluation of sunitinib malate in second-line treatment of metastatic renal cell carcinoma in Finland.
Purmonen T; Martikainen JA; Soini EJ; Kataja V; Vuorinen RL; Kellokumpu-Lehtinen PL
Clin Ther; 2008 Feb; 30(2):382-92. PubMed ID: 18343276
[TBL] [Abstract][Full Text] [Related]
3. Economic evaluation of new targeted therapies for the first-line treatment of patients with metastatic renal cell carcinoma.
Benedict A; Figlin RA; Sandström P; Harmenberg U; Ullén A; Charbonneau C; Sandin R; Remák E; Hariharan S; Négrier S
BJU Int; 2011 Sep; 108(5):665-72. PubMed ID: 21265994
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of everolimus for second-line treatment of metastatic renal cell carcinoma in Serbia.
Mihajlović J; Pechlivanoglou P; Sabo A; Tomić Z; Postma MJ
Clin Ther; 2013 Dec; 35(12):1909-22. PubMed ID: 24238790
[TBL] [Abstract][Full Text] [Related]
5. [A Cost-effectiveness Analysis of Sunitinib vs. Interferon-alpha in Patient with Advanced Renal Cell Carcinoma in Japan].
Tomura K; Naito Y; Sunaga T; Kurihara T; Usuda M; Nagatani A; Ogawa Y; Akiyama N; Sasaki H; Murata T; Sakamaki H; Kogo M; Sasaki T
Yakugaku Zasshi; 2018; 138(11):1397-1407. PubMed ID: 30381648
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness evaluation of sunitinib as first-line targeted therapy for metastatic renal cell carcinoma in Spain.
Calvo Aller E; Maroto P; Kreif N; González Larriba JL; López-Brea M; Castellano D; Martí B; Díaz Cerezo S
Clin Transl Oncol; 2011 Dec; 13(12):869-77. PubMed ID: 22126730
[TBL] [Abstract][Full Text] [Related]
7. A cost-effectiveness analysis of sunitinib in patients with metastatic renal cell carcinoma intolerant to or experiencing disease progression on immunotherapy: perspective of the Spanish National Health System.
Paz-Ares L; del Muro JG; Grande E; Díaz S
J Clin Pharm Ther; 2010 Aug; 35(4):429-38. PubMed ID: 20831545
[TBL] [Abstract][Full Text] [Related]
8. Potential health gains for patients with metastatic renal cell carcinoma in daily clinical practice: A real-world cost-effectiveness analysis of sequential first- and second-line treatments.
De Groot S; Blommestein HM; Redekop WK; Sleijfer S; Kiemeney LALM; Oosterwijk E; Uyl-de Groot CA
PLoS One; 2017; 12(5):e0177364. PubMed ID: 28531203
[TBL] [Abstract][Full Text] [Related]
9. Economic evaluation of everolimus versus sorafenib for the treatment of metastatic renal cell carcinoma after failure of first-line sunitinib.
Casciano R; Chulikavit M; Di Lorenzo G; Liu Z; Baladi JF; Wang X; Robertson J; Garrison L
Value Health; 2011; 14(6):846-51. PubMed ID: 21914504
[TBL] [Abstract][Full Text] [Related]
10. How do cost-effectiveness analyses inform reimbursement decisions for oncology medicines in Canada? The example of sunitinib for first-line treatment of metastatic renal cell carcinoma.
Chabot I; Rocchi A
Value Health; 2010; 13(6):837-45. PubMed ID: 20561332
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of pazopanib versus sunitinib for renal cancer in the United States.
Delea TE; Amdahl J; Diaz J; Nakhaipour HR; Hackshaw MD
J Manag Care Spec Pharm; 2015 Jan; 21(1):46-54, 54a-b. PubMed ID: 25562772
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of sunitinib in metastatic renal cell carcinoma.
Purmonen TT
Expert Rev Pharmacoecon Outcomes Res; 2011 Aug; 11(4):383-93. PubMed ID: 21831017
[TBL] [Abstract][Full Text] [Related]
13. Cost-Effectiveness Analysis of Sunitinib versus Interferon-Alfa for First-Line Treatment of Advanced and/or Metastatic Renal Cell Carcinoma in Singapore.
Pruis SL; Aziz MIA; Pearce F; Tan MH; Wu DB; Ng K
Int J Technol Assess Health Care; 2019 Jan; 35(2):126-133. PubMed ID: 30854989
[TBL] [Abstract][Full Text] [Related]
14. Bevacizumab, sorafenib tosylate, sunitinib and temsirolimus for renal cell carcinoma: a systematic review and economic evaluation.
Thompson Coon J; Hoyle M; Green C; Liu Z; Welch K; Moxham T; Stein K
Health Technol Assess; 2010 Jan; 14(2):1-184, iii-iv. PubMed ID: 20028613
[TBL] [Abstract][Full Text] [Related]
15. Economic evaluation of sunitinib versus pazopanib and best supportive care for the treatment of metastatic renal cell carcinoma in Chile: cost-effectiveness analysis and a mixed treatment comparison.
Vargas C; Balmaceda C; Rodríguez F; Rojas R; Giglio A; Espinoza MA
Expert Rev Pharmacoecon Outcomes Res; 2019 Oct; 19(5):609-617. PubMed ID: 30758237
[No Abstract] [Full Text] [Related]
16. [Economic evaluation of targeted biologic therapy in metastatic renal cell carcinoma].
Ondrácková B; Demlová R; Komínek J
Klin Onkol; 2010; 23(6):439-45. PubMed ID: 21351422
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of Pazopanib Versus Sunitinib as First-line Treatment for Locally Advanced or Metastatic Renal Cell Carcinoma from an Italian National Health Service Perspective.
Capri S; Porta C; Delea TE
Clin Ther; 2017 Mar; 39(3):567-580.e2. PubMed ID: 28189363
[TBL] [Abstract][Full Text] [Related]
18. Cost-effectiveness analysis of sunitinib in patients with metastatic and/or unresectable gastrointestinal stroma tumours (GIST) after progression or intolerance with imatinib.
Paz-Ares L; García del Muro X; Grande E; González P; Brosa M; Díaz S
Clin Transl Oncol; 2008 Dec; 10(12):831-9. PubMed ID: 19068454
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of everolimus vs sunitinib in treating patients with advanced, progressive pancreatic neuroendocrine tumors in the United States.
Casciano R; Chulikavit M; Perrin A; Liu Z; Wang X; Garrison LP
J Med Econ; 2012; 15 Suppl 1():55-64. PubMed ID: 22881362
[TBL] [Abstract][Full Text] [Related]
20. Cost-effectiveness of pazopanib versus sunitinib for metastatic renal cell carcinoma in the United Kingdom.
Amdahl J; Diaz J; Sharma A; Park J; Chandiwana D; Delea TE
PLoS One; 2017; 12(6):e0175920. PubMed ID: 28636648
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
